T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

SGLT2 Inhibition

EMPA-REG OUTCOME: Study Design

EMPA-REG OUTCOME: Key Inclusion and Exclusion Criteria

EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on the Primary Composite Outcome

EMPA-REG OUTCOME : Effect of Empagliflozin vs Placebo on Individual MACE Endpoints

EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on CV Death

EMPA-REG OUTCOME: HF Hospitalization or CV Death

EMPA-REG OUTCOME: HF Hospitalization or Death from HF

EMPA-REG OUTCOME: Investigator-Reported HF

EMPA-REG OUTCOME: HF Hospitalization in Patients With vs Without HF at Baseline

EMPA-REG OUTCOME: HF Hospitalization or CV Death in Patients With vs Without HF at Baseline

EMPA-REG OUTCOME: CV Medication Use

ADA/EASD Position Statement: Antihyperglycemic Therapy in T2DM

EMPA-REG OUTCOME: Baseline CV Complications

Ongoing SGLT2 Inhibitor CV Outcomes Trials

Abbreviations

Abbreviations (cont)